Subscribe to RSS
DOI: 10.1055/a-1906-4769
TC-325 hemostatic powder in the management of upper gastrointestinal malignant bleeding: a randomized controlled trial
TRIAL REGISTRATION: Randomized study NCT02820077 at ClinicalTrials.gov (http://www.clinicaltrials.gov/)
Abstract
Background and study aims Upper gastrointestinal bleeding (UGIB) from malignancy is associated with high rebleeding and mortality rates. Recently, TC-325 powder has shown promising results in the treatment of UGIB, including malignant bleeding. The aim of this study was to compare the efficacy of TC-325 versus best clinical management.
Patients and methods From August 2016 to February 2020, all patients with evidence of UGIB from malignancy were randomized to receive TC-325 therapy or control group, in which endoscopic treatment was not mandatory. Exclusion criteria were hemoglobin drop without overt bleeding and UGIB from non-tumor origin. The primary outcome was 30-day mortality. Secondary outcomes were 30-day rebleeding, blood transfusion and length of hospital stay.
Results Sixty-two patients were randomized, three were excluded and 59 were included in the final analysis (TC-325 group = 28; control = 31). Groups were similar at baseline. Active bleeding was observed in 22 patients in the TC-325 group and 19 in the control group (P = 0.15). Successful initial hemostasis with TC-325 was achieved in all cases. Additional therapy (radiotherapy, surgery or arterial embolization) was equally performed in both groups (42.9 % vs 58.1 %; P = 0.243). There were no differences in 30-day mortality (28.6 % vs. 19.4 %, P = 0.406) or 30-day rebleeding rates (32.1 % vs. 19.4 %, P = 0.26). Logistic regression identified no significant predictors of rebleeding. Age, Eastern Cooperative Oncology Group (ECOG) score 3 to 4 and AIMS65 score > 1 predicted greater mortality.
Conclusions TC-325 was effective in achieving immediate hemostasis in malignant gastrointestinal bleeding but did not reduce 30-day mortality, 30-day rebleeding, blood transfusion or length of hospital stay. Age, ECOG 3–4, and AIMS65 > 1 were predictive factors of mortality.
Publication History
Received: 30 January 2022
Accepted after revision: 20 July 2022
Accepted Manuscript online:
21 July 2022
Article published online:
17 October 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Maluf-filho F, Martins BC, De Lima MS. et al. Etiology, endoscopic management and mortality of upper gastrointestinal bleeding in patients with cancer. United Eur Gastroenterol J 2013; 1: 60-67
- 2 Loftus EV, Alexander GL, Ahlquist DA. et al. Endoscopic treatment of major bleeding from advanced gastroduodenal malignant lesions. Mayo Clin Proc 1994; 69: 736-740
- 3 Savides TJ, Jensen DM, Cohen J. et al. Severe upper gastrointestinal tumor bleeding: endoscopic findings, treatment, and outcome. Endoscopy 1996; 28: 244-248
- 4 Chen YI, Wyse J, Lu Y. et al. TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial. Gastrointest Endosc 2020; 91: 321-328.e1
- 5 Martins BC, Wodak S, Gusmon CC. et al. Argon plasma coagulation for the endoscopic treatment of gastrointestinal tumor bleeding: A retrospective comparison with a non-treated historical cohort. United Eur Gastroenterol J 2016; 4: 49-54
- 6 Mathus-Vliegen EMH, Tytgat GNJ. Analysis of Failures and complications of neodymium: YAG laser photocoagulation in gastrointestinal tract tumors. Endoscopy 1990; 22: 17-23
- 7 Heller SJ, Tokar JL, Nguyen MT. et al. Management of bleeding GI tumors. Gastrointest Endosc 2010; 72: 817-824
- 8 Ahn D, Lee SH, Park YS. et al. Hemostatic efficacy and clinical outcome of endoscopic treatment of Dieulafoyʼs lesions : comparison of endoscopic hemoclip placement and endoscopic band ligation. YMGE 2012; 75: 32-38
- 9 Aziz M. Efficacy of Hemospray in non-variceal upper gastrointestinal bleeding: a systematic review with meta-analysis. Ann Gastroenterol 2020; DOI: 10.20524/aog.2020.0448.
- 10 Mutneja HR, Bhurwal A, Go A. et al. Efficacy of hemospray in upper gastrointestinal bleeding: a systematic review and meta-analysis. J Gastrointest Liver Dis 2020; 29: 69-76
- 11 Shin J, Cha B, Park J-S. et al. Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding. BMC Gastroenterol 2021; 21: 40
- 12 Kim Y, Park J, Kim E. et al. Hemostatic powder application for control of acute upper gastrointestinal bleeding in patients with gastric malignancy. Endosc Int Open 2018; 06: E700-E705
- 13 Pittayanon R, Prueksapanich P, Rerknimitr R. The efficacy of Hemospray in patients with upper gastrointestinal bleeding from tumor. Endosc Int open 2016; 4: E933-E936
- 14 Pittayanon R, Rerknimitr R, Barkun A. Prognostic factors affecting outcomes in patients with malignant GI bleeding treated with a novel endoscopically delivered hemostatic powder. Gastrointest Endosc 2018; 87: 994-1002
- 15 Chen Y-I, Barkun AN. Hemostatic powders in gastrointestinal bleeding. Gastrointest Endosc Clin N Am 2015; 25: 535-552